New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 27, 2012
09:40 EDTIDIX, DV, ACO, RYL, JOE, F, DK, ABFS, RVBD, JNPR, ESIO, CLF, ABAX, MSCCGappers report: Bearish gaps
This is a list of stocks making unusual moves on the open versus the prior day close. Gapping stocks often have excessive movements during the day and in the days thereafter. We use 5% for filter criteria and scanned for stocks that traded above $10 the prior day. GAPPING DOWN: RVBD (19.95%), ESIO (15.62%), IDIX (11.72%), ACO (11.44%), ABFS (11.11%), JNPR (10.77%), MSCC (8.73%), ABAX (8.72%), DV (7.18%), RYL (6.57%), F (6.49%), CLF (5.65%), DK (5.32%), JOE (5.23%).
News For ABAX;ABFS;ACO;CLF;DK;DV;ESIO;F;IDIX;JNPR;JOE;MSCC;RVBD;RYL From The Last 14 Days
Check below for free stories on ABAX;ABFS;ACO;CLF;DK;DV;ESIO;F;IDIX;JNPR;JOE;MSCC;RVBD;RYL the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | all recent news | >>
April 9, 2014
07:48 EDTCLFBofA/Merrill's steel analysts hold an analyst/industry conference call
Subscribe for More Information
07:23 EDTIDIXEuropean Association for the Study of the Liver to hold annual meeting
Subscribe for More Information
06:40 EDTFCar sales rose 9% last month in China, China Daily says
Subscribe for More Information
05:24 EDTFFord Focus retains best-selling vehicle title in 2013
Subscribe for More Information
April 8, 2014
11:47 EDTIDIXIdenix price target raised to $9 from $6 at Leerink
Leerink raised Idenix's price target to $9 from $6 citing positive IDX21437 data.
08:44 EDTFFord says China sales cross 100,000 mark in March, March sales up 28% y/y
Subscribe for More Information
08:02 EDTABAXAbaxis receives Health Canada Class III approval for Piccolo Xpress
Abaxis announced Health Canada approved the Piccolo Xpress and Piccolo Reagent Discs as a Class III medical device for use throughout Canada. With this reclassification, Canadian healthcare providers and patients can now enjoy the benefits of lab-accurate blood chemistry diagnostics at the point-of-care.
07:52 EDTDKRefiners 2014 EPS estimates raised at Wells Fargo
Wells Fargo significantly raised its 2014 EPS estimates for Alon USA (ALJ), PBF Energy (PBF), Valero (VLO), and Western Refining (WNR) . The firm thinks that the sector is benefiting from better crack spreads and refining utilization so far in Q2, while U.S. exports of refined products jumped 21% year-over-year last quarter. Wells keeps Outperform ratings on PBF and Valero, and Market Perform ratings on Alon USA and Western Refining.
06:38 EDTFFord's March China sales up 28% y/y, Reuters reports
Subscribe for More Information
April 7, 2014
16:28 EDTIDIXOn The Fly: Closing Wrap
Subscribe for More Information
13:31 EDTIDIXIdenix risk/reward remains favorable, says UBS
UBS said Idenix's IDX21437 update this morning supports its favorable risk/reward thesis. Shares are Buy rated with an $11 price target.
12:47 EDTFFord recalls 434,000 vehicles in two unrelated recalls, Detroit News reports
Ford is recalling more than 434,000 vehicles in two separate recalls announced Monday, reports Detroit News. The company is recalling 385,750 Escape compact SUVs due to a rusty subframe. it also will recall 48,950 Ford Fusion, Lincoln MKZ, Ford Escape and C-Max vehicles to replace seatback frames that don't comply to the NHTSA standard. Reference Link
07:15 EDTIDIXIdenix announces promising clinical data, continued progress in HCV programs
Idenix Pharmaceuticals announced continued progress of the Company's program to develop nucleotide prodrug inhibitors for the treatment of hepatitis C virus, or HCV, infection. Idenix is reporting potent antiviral activity of mean maximum 4.2-4.3 log10 IU/mL reductions for patients infected with HCV genotype 1, 2 or 3 receiving 300 mg once daily of IDX21437 in the seven-day proof-of-concept portion of a phase I/II clinical trial. Based on this progress, the Company's goal is to initiate a combination clinical trial of IDX21437 and samatasvir, a pan-genotypic NS5A inhibitor, in mid-2014. In addition, Idenix has selected a follow-on uridine-based nucleotide prodrug, IDX21459, from its ongoing nucleotide discovery program and initiated enrollment for the healthy volunteer portion of a phase I clinical trial. In January, Idenix initiated the seven-day proof-of-concept portion of a phase I/II clinical trial for IDX21437. The trial completed enrollment of 44 treatment-nave, genotype, or GT, 1, 2 or 3 HCV-infected patients. Patients were randomized to receive once-daily doses of placebo, 50 mg, 150 mg, or 300 mg of IDX21437 for seven days. In April 2014, Idenix initiated enrollment for the healthy volunteer portion of a phase I clinical trial of IDX21459 in Europe. This portion of the study is expected to enroll approximately 50 healthy volunteers and will evaluate once-daily doses of IDX21459 ranging from 10 mg 300 mg. The proof-of-concept portion of the study is expected to enroll a total of 40 treatment-nave, genotype 1 HCV-infected patients who will receive once-daily doses of placebo, 50 - 300 mg of IDX21459 for seven days. IDX21459 has shown a favorable preclinical profile including potent, pan-genotypic activity and favorable safety with respect to cardiac, mitochondrial and genotoxicity assessments.
05:25 EDTFFord Transit Connect awarded five star safety rating by NHTSA
Subscribe for More Information
April 4, 2014
10:02 EDTJNPROn The Fly: Analyst Initiation Summary
Subscribe for More Information
07:55 EDTFFord outpacing rivals in China on strength of SUVs, WSJ says
Thanks in large part to a rising demand in China for sport-utility vehicles, Ford's (F) China deliveries jumped past Toyota (TM) in 2013 and the U.S. automaker also gained on General Motors (GM) and Volkswagen (VLKAY), who it has similarly trailed in China for years, reported The Wall Street Journal. Reference Link
April 3, 2014
16:37 EDTJNPROn The Fly: Closing Wrap
Subscribe for More Information
16:13 EDTJNPRJuniper initiated with a Market Perform at Northland Securities
09:30 EDTFApple, Pfizer others create 'go slow' patent lobby group, Reuters says
Subscribe for More Information
07:40 EDTDVChanos says still short names in for-profit education space
Subscribe for More Information
1 | 2 | 3 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use